Armstrong Advisory Group’s Axsome Therapeutics AXSM Stock Holding History

Armstrong Advisory Group’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$104K	Hold	423	–	–	0.01%	343
2026 Q1	$71.5K	Hold	423	–	–	﹤0.01%	359
2025 Q4	$77.3K	Hold	423	–	–	0.01%	341
2025 Q3	$51.4K	Hold	423	–	–	﹤0.01%	393
2025 Q2	$44.2K	Hold	423	–	–	﹤0.01%	400
2025 Q1	$35.8K	Hold	423	–	–	﹤0.01%	419
2024 Q4	$35.8K	Hold	423	–	–	﹤0.01%	419
2024 Q3	$38K	Hold	423	–	–	﹤0.01%	404
2024 Q2	$34.1K	Hold	423	–	–	﹤0.01%	406
2024 Q1	$33.7K	Hold	423	–	–	﹤0.01%	398
2023 Q4	$33.7K	Hold	423	–	–	﹤0.01%	398
2023 Q3	$29.6K	Hold	423	–	–	﹤0.01%	414
2023 Q2	$30.4K	Hold	423	–	–	﹤0.01%	414
2023 Q1	$26.1K	Hold	423	–	–	﹤0.01%	430
2022 Q4	$32.6K	Buy	+423	New	+$25.3K	﹤0.01%	404

Other funds holding AXSM

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

BWP

Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

TAM

Tealwood Asset Management Minneapolis, Minnesota $261M AUM 52.68% 1-Year Est. Return

Cannon Advisors Charlotte, North Carolina $164M AUM 30.34% 1-Year Est. Return

MCP

Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return

Armstrong Advisory Group's AXSM Position: Q2 2026 in Review

Armstrong Advisory Group held its Axsome Therapeutics (AXSM) position steady in Q2 2026 at 423 shares worth $104K. The position accounts for 0.01% of the portfolio, ranked #343.

Armstrong Advisory Group first reported a position in AXSM in Q4 2022 and has held it in 15 quarters since. 38 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Armstrong Advisory Group held 423 shares of Axsome Therapeutics worth $104K as of Q2 2026.
Armstrong Advisory Group left its Axsome Therapeutics share count unchanged in Q2 2026.
Axsome Therapeutics made up 0.01% of Armstrong Advisory Group's portfolio in Q2 2026, its #343 holding.
Armstrong Advisory Group first reported a position in Axsome Therapeutics in Q4 2022 and has held it in 15 quarters since.
38 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Armstrong Advisory Group's 13F filing for Q2 2026, filed 13 Jul 2026.